Metastatic Brain Tumor

Symptoms

Symptoms depend on the number, size, and location of the metastases and the pressure they create within the brain. Common features include headaches, seizures, weakness or numbness, difficulty with speech or coordination, vision changes, and changes in thinking or personality.

Much of the early difficulty often comes from swelling in the brain around the metastasis rather than from the tumor itself, which is why symptoms frequently improve within a day or two of starting steroid medication. In about one patient in ten, a brain metastasis is the first sign of a cancer that has not yet been diagnosed.

Because metastases can grow relatively quickly and raise pressure inside the skull, new or progressing neurological symptoms in anyone with a history of cancer warrant prompt evaluation — including cancer treated years earlier and considered resolved. Some metastases, particularly from melanoma, kidney, and thyroid cancer, can bleed, producing symptoms that begin suddenly rather than over days.

Diagnosis

MRI and Imaging

MRI with contrast is the key imaging study. Metastases have a fairly characteristic appearance: well-defined enhancing lesions, often multiple, typically sitting at the junction between gray and white matter where blood vessels narrow, and usually surrounded by an area of swelling that looks disproportionately large for the size of the tumor.

In a person with known cancer, imaging alone may strongly suggest the diagnosis. Thin-slice imaging is important because small metastases are the ones most easily treated with radiosurgery and most easily missed on standard sequences.

When a Biopsy May Be Needed

When the primary cancer is unknown, or when the imaging could represent something other than a metastasis, biopsy tissue is needed for diagnosis. Evaluation usually begins with imaging of the chest, abdomen, and pelvis or a PET scan to look for the primary tumor.

When no primary is found, or when the brain lesion itself is causing symptoms, biopsy or surgical removal of the brain lesion provides the diagnosis. Staging of the rest of the body also establishes how well the cancer is controlled elsewhere, which is one of the strongest factors in deciding how aggressively to treat the brain.

Why Molecular Testing Matters

A metastasis does not always carry the same molecular alterations as the primary tumor it came from, and testing brain tissue sometimes identifies a treatment target that testing of the original cancer did not show — or shows that a drug the patient is taking is no longer matched to the disease in the brain.

For a patient whose cancer has been treated for years, this can change the systemic plan, not just the brain plan.

What Guides Treatment Decisions

Deciding how aggressively to treat the brain is a judgment made with the whole picture in mind: the type and molecular profile of the primary cancer, how well disease elsewhere in the body is controlled, how the patient is functioning, age, and the total volume of tumor in the brain.

Formal scoring systems exist to support that judgment and now incorporate molecular markers. What has changed is that the number of metastases, once the dominant consideration, now carries less weight than the total volume of disease and the biology of the cancer.

After Radiosurgery: Recurrence vs. Radiation Necrosis

Imaging after radiosurgery requires careful interpretation. Months to years after treatment, a treated metastasis can enlarge and enhance again on MRI because of the effects of radiation on surrounding tissue rather than because the tumor has regrown — a phenomenon called radiation necrosis.

The two look similar on a standard MRI and are managed very differently. Distinguishing them relies on the timing relative to treatment, perfusion and other advanced imaging, the pattern of change across serial scans, and occasionally tissue sampling.

This is one of the clearest reasons for follow-up imaging to be read by neuroradiologists who see these cases regularly and reviewed alongside the team that delivered the treatment.

Treatment

Treatment for metastatic brain tumors is individualized based on the number, size and location of the brain metastases, the type and status of the primary cancer — including its molecular profile, previous treatments and the patient’s overall health. Care is coordinated with the patient’s medical oncology and radiation oncology teams so treatment of the brain metastases fits into the overall cancer plan.

Stereotactic Radiosurgery (SRS)

Stereotactic radiosurgery delivers highly focused radiation to brain metastases without an incision, usually in one to five sessions, with the dose falling off sharply at the edge of the target so that surrounding brain receives very little. It is the primary treatment for most brain metastases and can treat several in a single session.

This represents a real change from how these tumors were treated a generation ago. Whole-brain radiation was once standard for anyone with more than one or two metastases, and randomized trials subsequently showed that it caused significantly more decline in memory and thinking than focused treatment, without helping patients live longer.

Whole-brain radiation still has a role — in widespread disease, in certain cancer types, and when metastases keep appearing. When it is used, techniques that shield the memory structures of the brain and medication given alongside it can reduce its cognitive cost. But it is no longer the default, and the number of metastases matters less in that decision than it once did.

Surgery

Surgery is recommended for tumors too large for radiosurgery to control safely, for tumors causing significant pressure or neurological symptoms, for metastases in the back of the brain that threaten to block the flow of spinal fluid, and when tissue is needed to establish the diagnosis.

Removing a symptomatic metastasis often produces rapid improvement in a way no other treatment can match. Where the tumor’s location allows, it is removed in one piece rather than in fragments, which reduces the chance of tumor cells being carried into the spinal fluid.

Surgery is nearly always followed by focused radiation to the surgical cavity, which substantially reduces the chance of the tumor returning at that site.

Targeted Therapy & Immunotherapy

Systemic therapy has changed this disease more than anything else in the past decade. Drugs were long assumed not to reach the brain in useful concentrations, and for older chemotherapy that was largely true. It is no longer true of many newer agents.

Certain targeted therapies for lung cancer with EGFR or ALK alterations produce high rates of response in the brain. Combinations directed at HER2-positive breast cancer are active against established brain metastases. In melanoma, both targeted therapy and immunotherapy produce durable control of brain disease in a meaningful proportion of patients.

For some patients with small, symptom-free metastases and a cancer carrying the right molecular target, it is now reasonable to begin systemic therapy and follow the brain closely, holding radiation in reserve. That decision depends entirely on which cancer it is and what molecular alterations it carries, and it is made together with the medical oncology team.

Coordinating Your Treatment

At Atlantic Brain and Spine, these cases are reviewed by a multidisciplinary brain tumor team working directly with the medical and radiation oncologists treating the cancer as a whole.

Sequence matters as much as selection — whether radiation comes before or after a change in systemic therapy, and whether surgery precedes radiosurgery, affects both how well the brain disease is controlled and whether systemic treatment has to be interrupted. Those decisions are made in one conversation rather than in parallel ones.

For many patients, the outlook is very different than it was a decade ago. Metastases can be controlled for years while the cancer elsewhere is treated, and treatment of the brain disease is now planned with that timescale in mind — preserving thinking, memory and function over the long run, not simply shrinking tumors.